

EMORD & ASSOCIATES P.C.

BURKE PROFESSIONAL CENTER
5282 LYGATE COURT
BURKE, VIRGINIA 22015

1050 SEVENTEENTH STREET, N.W. 7 153 '04 4 25 P1
SUITE 600
WASHINGTON, D.C. 20036

PHONE: (202) 466-6937 • FAX: (202) 466-6938
WEB SITE: www.emord.com
E-MAIL: aferrenz@emord.com

April 5, 2004

VIA EMAIL *Kathy.ellwood@cfsan.fda.gov*

AND UPS GROUND

Dr. Kathy Ellwood
Assistant Director for Nutrition Science
FDA, CFSAN
CPK 1, Room 4A026, HFS-800
5100 Paint Branch Parkway
College Park MD 20740

Re: Glucosamine and Chondroitin Sulfate Health Claim Petition

Dear Dr. Ellwood:

This will confirm that our client, Weider Nutrition International Inc., agrees to FDA's proposal to issue its decision on the following claims no later than sixty (60) days following the Food Advisory Committee meeting on this petition:

Glucosamine may reduce the risk of osteoarthritis
Chondroitin sulfate may reduce the risk of osteoarthritis
Glucosamine and chondroitin sulfate may reduce the risk of osteoarthritis

Weider further agrees to FDA's proposal to issue its decision on the following claims no later than ninety (90) days following the FAC meeting on this petition.


Glucosamine may reduce the risk of joint degeneration
Chondroitin sulfate may reduce the risk of joint degeneration
Glucosamine and chondroitin sulfate may reduce the risk of joint degeneration
Glucosamine may reduce the risk of cartilage deterioration.
Chondroitin sulfate may reduce the risk of cartilage deterioration
Glucosamine and chondroitin sulfate may reduce the risk of cartilage deterioration

2004P-0059

LET 4

Please contact us if you have any questions regarding this letter.

Sincerely,



Jonathan W. Emord
Andrea G. Ferrenz

Cc: Weider Nutrition International Inc.